Small Pharma Inc. (CVE:DMT – Get Free Report)’s stock price was down 6.3% on Friday . The company traded as low as C$0.15 and last traded at C$0.15. Approximately 1,890,765 shares were traded during trading, an increase of 538% from the average daily volume of 296,159 shares. The stock had previously closed at C$0.16.
Small Pharma Price Performance
The company has a debt-to-equity ratio of 5.95, a current ratio of 2.63 and a quick ratio of 6.28. The company has a market cap of C$50.37 million, a P/E ratio of -2.14 and a beta of 0.86. The company has a fifty day simple moving average of C$0.15 and a 200-day simple moving average of C$0.15.
About Small Pharma
Small Pharma Inc, a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
See Also
- Five stocks we like better than Small Pharma
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- How to Invest in the Best Canadian Stocks
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for Small Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Small Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
